1-3 of 3
Monty Hankin
Close
Sort by
Journal Articles

Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study

Aristoteles Giagounidis, MD PhD, Uwe Platzbecker, MD, Ulrich Germing, MD, Katharina Götze, MD, Philipp Kiewe, MD, Karin Tina Mayer, MD, Oliver Ottmann, MD, Markus Radsak, MD, Thomas Wolff, MD, Detlef Haase, MD, Monty Hankin, Dawn Wilson, Xiaosha Zhang, Adberrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD
Journal: Blood
Blood (2015) 126 (23): 92.
https://doi.org/10.1182/blood.V126.23.92.92
Published: 2015
Journal Articles

Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study

Uwe Platzbecker, MD, Ulrich Germing, MD, Aristoteles Giagounidis, MD PhD, Katharina Götze, MD, Philipp Kiewe, MD, Karin Tina Mayer, MD, Oliver Ottmann, MD, Markus Radsak, MD, Thomas Wolff, MD, Detlef Haase, MD, Monty Hankin, Dawn Wilson, Xiaosha Zhang, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD
Journal: Blood
Blood (2015) 126 (23): 2862.
https://doi.org/10.1182/blood.V126.23.2862.2862
Published: 2015
Journal Articles

ACE-536 Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from a Phase 2 Study

Uwe Platzbecker, MD, Ulrich Germing, MD, Aristoteles Giagounidis, MD PhD, Katharina Goetze, MD, Philipp Kiewe, MD, Karin Mayer, MD, Oliver Ottman, MD, Markus P. Radsak, MD, Thomas Wolff, MD, Detlef Haase, MD, Monty Hankin, Dawn M. Wilson, Adberrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD
Journal: Blood
Blood (2014) 124 (21): 411.
https://doi.org/10.1182/blood.V124.21.411.411
Published: 2014